Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Non Probability Sampling

Inclusion Criteria:

• Male and Female patients 18 to 65 y/old
• Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
• Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

Exclusion Criteria:

• Pregnant of Lactating women
• History of secondary hypertension